Companies /Healthcare

Agilent Technologies Inc

NYSE: A Diagnostics & Research
$157.88
â–² $2.80 (+1.80%) today
Markets open · 12:51pm ET

Q4 2025 Earnings

Reported Nov 24, 2025, 4:11pm ET · SEC source
$1.59
Beat +0.37%
EPS · est. $1.58
$1.9B
Beat +1.56%
Revenue · est. $1.8B
−14.2%
Trailing market
A vs S&P since report
2 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+4%+8%Nov 24Nov 25report 4:11pm ETearnings+0.9%+8.4%
0+4%+8%Nov 24Nov 25earnings+0.9%+8.4%
A +8.4%S&P 500 +0.9%
0+4%+8%Nov 24Nov 25report 4:11pm ETearnings+0.5%+8.4%
0+4%+8%Nov 24Nov 25earnings+0.5%+8.4%
A +8.4%NASDAQ +0.5%
0+2%+4%Nov 24Dec 2report 4:11pm ETearnings+1.9%−1.5%
0+2%+4%Nov 24Dec 2earnings+1.9%−1.5%
A −1.5%S&P 500 +1.9%
0+2%+4%Nov 24Dec 2report 4:11pm ETearnings+2.7%−1.5%
0+2%+4%Nov 24Dec 2earnings+2.7%−1.5%
A −1.5%NASDAQ +2.7%
+2.34%
Day of report
−1.80%
Next session
−5.05%
One week
−12.26%
30 days

S&P 500 over the same 30 days: +1.90%.

Did A Beat Earnings? Q4 2025 Results

Agilent Technologies closed out fiscal 2025 on a strong note, posting Q4 revenue of $1.86 billion, up 9.4% year-over-year and ahead of the $1.83 billion consensus estimate, while non-GAAP EPS of $1.59 edged past the $1.58 Wall Street forecast. The results reflected broad-based momentum across all three business segments, with the Life Sciences and Diagnostics Markets Group leading the charge at 15% reported revenue growth, underscoring a recovery in demand that had weighed on the company in prior periods. The Agilent CrossLab Group remained the largest contributor for the full fiscal year at $2.91 billion in revenue with a 32.5% operating margin, lending the business a recurring revenue stability that analysts have noted as a key valuation anchor, much as investors in other diagnostics and life science names have rewarded <a href="https://247wallst.com/investing/2025/11/03/idexx-laboratories-jumps-15-on-q3-earnings-beat/">consistent earnings execution</a>. Looking ahead, Agilent guided FY2026 revenue to $7.30 billion to $7.40 billion with non-GAAP EPS of $5.86 to $6.00, signaling continued confidence in its growth trajectory.

Key Takeaways
  • Life Sciences and Diagnostics Markets Group led Q4 growth with 15% reported revenue increase (11% core)
  • Revenue exceeded guidance in both Q4 and full fiscal year 2025
  • Ignite Operating System driving operating efficiencies and commercial execution
  • Unified commercial organization delivering seamless end-to-end customer experience

“We enter FY26 with confidence and momentum. Agilent is uniquely positioned to lead in life-sciences and diagnostics for years to come.”

Agilent Technologies CEO, on the earnings call

Forward Guidance & Outlook

For fiscal year 2026, Agilent expects revenue in the range of $7.3 billion to $7.4 billion, representing 5% to 7% reported growth and 4% to 6% core growth. Non-GAAP EPS is expected in the range of $5.86 to $6.00. For Q1 FY2026, revenue guidance is $1.79 billion to $1.82 billion (6% to 8% reported growth, 4% to 6% core), with non-GAAP EPS of $1.35 to $1.38. The outlook is based on forecasted currency exchange rates.

A YoY Financials

Q4 2025 vs Q4 2024 · SEC filings Q4 2024 Q4 2025
$0$600.0M$1.2B$1.8B$1.7B$1.9BRevenue$916.0M$990.0MGross Profit$408.0M$443.0MOperating Income$351.0M$434.0MNet Income
$0$600.0M$1.2B$1.8BRevenueGross ProfitOperating IncomeNet Income

A Revenue by Segment

Agilent CrossLab Group$755.0M+7.0%
Life Sciences and Diagnostics Markets Group$755.0M+15.0%
Applied Markets Group$351.0M+4.0%

Figures from SEC filings and company reports. Not investment advice.